A-share subscription | Tainuo Maibo (688806.SH) starts subscription for the world's first approved Staduta monoclonal antibody injection.

On July 10th, Taimei Biopharmaceutical (688806.SH) initiated its IPO with an issuance price of 14.46 yuan per share and a maximum subscription limit of 11,500 shares, listed on the Shanghai Stock Exchange, with Huatai as its sponsor. According to the prospectus, the company was founded in 2015 and is an innovative biopharmaceutical company dedicated to blood product replacement therapy for the global market. The company is focused on creating clinical value, following a strategy of differentiated innovation and competition, and is committed to the development, manufacturing, commercialization, and potential substitution of globally specific blood products, in order to meet a wide range of clinical needs and benefit patients. The company's core product, Staduta monoclonal antibody injection (recombinant anti-tetanus toxin human monoclonal antibody TNM002, commercial name: Xintitu), was approved for market in China in February 2025, making it the first-in-class recombinant anti-tetanus toxin monoclonal antibody drug globally. It has been recognized by China's CDE as a breakthrough therapy and included in the priority review process, and granted FastTrack designation by the US FDA, with significant innovative significance in the field of tetanus prevention. Another core product, recombinant anti-respiratory syncytial virus human monoclonal antibody TNM001, has been submitted for NDA for both non-high-risk and high-risk infant populations, and has also been included in the priority review process. Over the years, the company has built up core technological platforms with independent intellectual property rights, such as the HitmAb high-throughput human monoclonal antibody R&D comprehensive technology platform, high-efficiency antibody expression CHO-GS cell platform, process development platform, bioanalytical platform, etc. These platforms have continuously cultivated and enhanced key drug R&D and industrialization capabilities covering drug discovery, engineered cell construction, process and quality development, pharmacological studies, toxicological studies, pharmacokinetic studies, clinical development, and international GMP-compliant large-scale production. The company's candidate antibody drugs incubated through the HitmAb platform have matured antibody structures selected through real human immune tolerance environments, are fully humanized antibodies with strong specificity, high affinity, and superior safety, effectively reducing adverse consequences of antibody immunogenicity, mitigating clinical safety risks, and increasing the probability of a successful drug outcome. Based on the above core technological platforms, as of the date of the prospectus, the company has developed multiple antibody molecules as candidate drugs, covering infectious diseases and diseases in the pain category, among others. The globally innovative Staduta monoclonal antibody injection has been approved for market, TNM001 (anti-respiratory syncytial virus RSV monoclonal antibody) has been submitted for NDA for non-high-risk and high-risk infants and accepted for review, and two candidate drugs, TNM009 (anti-nerve growth factor NGF monoclonal antibody) and TNM005 (anti-varicella-zoster virus VZV monoclonal antibody), have completed Phase I clinical trials, with one candidate drug, TNM006 (anti-human cytomegalovirus HCMV monoclonal antibody) approved for IND, and three candidate drugs in preclinical stages. Staduta monoclonal antibody injection and TNM005 among these products are globally innovative or have the potential for global innovation. In terms of finances, in 2024 and 2025, the company achieved operating revenues of approximately 15.06 million and 51.22 million yuan respectively, with net profits of approximately -515 million and -601 million yuan in the same period.